COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,686 Articles (22,913 medRxiv, 8,773 bioRxiv)

Most recent first Previous |  Page 1668: Articles 16671-16680  | Next

The allometric propagation of COVID-19 is explained by human travel
Tuladhar, R., Grigolini, P., Santamaria, F.
10.1101/2021.04.08.21255169 — Posted: 2021-04-13
Refining long-COVID by a prospective multimodal evaluation of patients with long-term symptoms related to SARS-CoV-2 infection
SCHERLINGER, M., Felten, R., Gallais, F., Nazon, C., Chatelus, E., Pijnenburg, L., Mengin, A., Gras, A., Vidailhet, P., Arnould-Michel, R., Bibi-triki, S., Carapito, R., Bahram, S., trouillet-assant, s., Perret, M., Belot, A., Arnaud, L., Gottenberg, J.-E., Fafi-Kremer, S., Sibilia, J.
10.1101/2021.04.08.21255167 — Posted: 2021-04-13
Compliance with Covid-19 measures: evidence from New Zealand
Kaine, G., Greenhalgh, S., Wright, V.
10.1101/2021.04.08.21255157 — Posted: 2021-04-13
Undergraduate student interest in healthcare career in the context of COVID-19 pandemic
Jo, S. Y., Li, J., Dewan, A., Cheng, Y.-C., Hou, H., Sebro, R. A.
10.1101/2021.04.11.438530 — Posted: 2021-04-12
The Seroprevalence of SARS-CoV-2 in Europe: A Systematic Review
Vaselli, N. M., Hungerford, D., Shenton, B., Khashkhusha, A., Cunliffe, N., French, N.
10.1101/2021.04.12.439425 — Posted: 2021-04-12
Inhibition of arenavirus entry and replication by the cell-intrinsic restriction factor ZMPSTE24 is enhanced by IFITM antiviral activity
Stott, R. J., Foster, T. L.
10.1101/2021.04.12.439453 — Posted: 2021-04-12
LRR protein RNH1 inhibits inflammasome activation through proteasome-mediated degradation of Caspase-1 and is associated with adverse clinical outcomes in COVID-19 patients.
Bombaci, G., Sarangdhar, M. A., Andina, N., Tardivel, A., Yu, E. C.-W., Mackie, G. M., Pugh, M., Ozan, V. B., Banz, Y., Spinetti, T., Hirzel, C., Youd, E., Schefold, J. C., Taylor, G. S., Gazdhar, A., Bonadies, N., Angelillo-Scherrer, A., Schneider, P. S., Maslowski, K. M., Allam, R.
10.1101/2021.04.12.438219 — Posted: 2021-04-12
Epitope profiling of coronavirus-binding antibodies using computational structural modelling
Robinson, S. A., Raybould, M. I. J., Marks, C., Schneider, C., Wong, W. K., Deane, C. M.
10.1101/2021.04.12.439478 — Posted: 2021-04-12
Interactions between SARS-CoV-2 N-protein and α-synuclein accelerate amyloid formation
Semerdzhiev, S., Fakhree, M. A. A., Segers-Nolten, I., Blum, C., Claessens, M. M. A. E.
10.1101/2021.04.12.439549 — Posted: 2021-04-12
Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by the broad-spectrum anti-infective drug nitazoxanide
Riccio, A., Santopolo, S., Rossi, A., Piacentini, S., Rossignol, J.-F., Santoro, M. G.
10.1101/2021.04.12.439201 — Posted: 2021-04-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).